Our team

Caroline Goddeeris holds a PhD in Pharmaceutical Sciences followed by an MBA and master in corporate finance, both from Vlerick Business School. She started her career at UCB taking on various roles in strategy (portfolio management, business development, new product planning) and operations (marketing and sales). Prior to joining Fund+, Caroline was a principal at Gimv with board responsibilities at Complix and Multiplicom (sold to Agilent). Caroline currently serves on the board of Confo Therapeutics, Tubulis and Astrivax.

Bart joined Fund+ in 2023.  Prior to joining Fund+, Bart worked at Ackermans & van Haaren as Group Controller and Investment Manager and as CFO/Risk Officer at Fortino Capital Partners. For most of his career, he worked at Ernst&Young where he progressed as Head of the Technical Desk. He was part of the EY global expert group in London. Bart holds a master’s degree in Commercial Sciences and in Business Information Systems from the University of Brussels. Bart is a Board Member of Coave & EyeD Pharmaceuticals.

Halina Novak, PhD, is a Principal at Fund+. Halina brings extensive experience in technology innovation, investment and alliance management. Formerly, Halina held several leadership positions at VIB, the Flemish Institute for Biotechnology and worked at the intersection between industry, pharma and academia, leading large multi-stakeholder collaborations. Notably, she headed the Tech Watch Program and established the Technology Innovation Lab, where unique strategies were developed to identify, invest and evaluate breakthrough life science technologies in collaboration with start-ups and pharma. Many of these early-stage investments in disruptive tools have since revolutionised the Life Sciences. Halina started her career at Unilever on a fellowship that developed novel applications of industrial enzymes after having graduated from the University of Exeter with a PhD and BSc in Biological Sciences and Biological and Medicinal Chemistry, respectively. Halina previously represented Fund+ as a board member of Cardior Pharmaceuticals which was acquired by Novo Nordisk and is currently representing Fund+ as a Board member of Egle Therapeutics and TargED Biopharmaceuticals and as a Board Observer of EyeD Pharma.

Patrick has built a strong track record of over 30 years in the life sciences, both in early and late-stage investments and exits, including Devgen, CropDesign, Plexxikon, Endosense, Crucell, Innogenetics and Ablynx. Prior to joining Fund+ as a Consultant in 2023, Patrick was a Partner at Gimv. Patrick is a Board Member of Ona Therapeutics, Minoryx and Novadip, representing Fund+ and also a Board Member at Biotalys. Patrick has a Master in Financial Sciences from Vlekho in Brussels, Belgium.

Diane holds a bachelor degree in informatics. She worked as administrative assistant and bookkeeper for several companies such as ADB (Siemens), VIB and Life Sciences Research Partners (still currently).